Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade

• Published in: Diabetologia Vol. 65; no. 7; pp. 1185 - 1197
• Main Authors: Kawada-Horitani, Emi, Kita, Shunbun, Okita, Tomonori, Nakamura, Yuto, Nishida, Hiroyuki, Honma, Yoichi, Fukuda, Shiro, Tsugawa-Shimizu, Yuri, Kozawa, Junji, Sakaue, Takaaki, Kawachi, Yusuke, Fujishima, Yuya, Nishizawa, Hitoshi, Azuma, Miyuki, Maeda, Norikazu, Shimomura, Iichiro
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2022; Springer Nature B.V
• Subjects: Animals; Antibodies, Monoclonal; Apoptosis; B7-H1 Antigen - metabolism; Beta cells; Cancer; Cancer therapies; CD3 antigen; Cell death; Chemokines; CTLA-4 protein; Cytokines; Cytotoxicity; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - metabolism; Fibrosis; Human Physiology; Humans; Immune Checkpoint Inhibitors; Immune system; Immunofluorescence; Immunomodulation; Insulin; Internal Medicine; Ligands; Lymphocytes; Lymphocytes T; Macrophages; Male; Medicine; Medicine & Public Health; Mesenchymal stem cells; Mesenchymal Stem Cells - metabolism; Metabolic Diseases; Metastases; Mice; Mice, Inbred NOD; Monoclonal antibodies; Monocytes; Neoplasms - metabolism; Patients; PD-1 protein; PD-L1 protein; Plasma; Programmed Cell Death 1 Receptor - metabolism; Stem cells; Tumors; Immune checkpoint inhibitor; NOD mouse; Mesenchymal stem cells

Aims/hypothesis Immunomodulators blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have improved the treatment of a broad spectrum of cancers. These immune checkpoint inhibitors (ICIs) reactivate the immune s...